Type 2 diabetes
Conditions
Interventions
sitagliptin administration group
Glimepiride administration group
Sponsors
St.Marianna University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Inadequately controlled type 2 diabetic patients who are not taking antidiabetic agent other than metformin for more than 2 month. Patients whose HbA1c ranges from 6.9% to 9.4%. 2)Patients who had Fatty liver, or Patients whose IHL(intrahepatic lipid content)is more than 10% on 1H-MRS, or Patients who had metabolic syndrome fulfilled the diagnostic criteria, or Patients whose BMI is more than 25. 3)Patients who have been received diabetes treatment for more than 6 months. 4)over 20 years age 5)Out patient 6)Gender is not restricted. 7)Patient understands study procedures and agrees to participate in the study by giving written informed consent prior to the study start.
Exclusion criteria
Exclusion criteria: 1)Patients who had diabetic ketosis, or diabetic pre-coma and coma within 6 months of the study entry. 2)Patients with severe infections, before or after operation, or with serious trauma. 3)Patients with pregnancy, possibility of pregnancy or having a breast feeding. 4)Patients with renal insufficiency (serum creatinine = and > 1.5 mg/dl) 5)Patients who received insulin therapy. 6)Patients who administered antihyperlipidemic agent other than Metformin for observation period. 7)Patients who had a history of hypersensitive reaction to DPP-4 inhibitor. 8)Patients whom the attending doctor estimated to be ineligible according to the medical rationale.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| amount of Intrahepatic adipose mass and visceral fat(MRI,DEXA) | — |
Countries
Japan
Contacts
Public ContactHiroyuki Kato
St.Marianna University School of Medicine Hospital Division of Endocrinology and Metabolism
Outcome results
None listed